Atopic dermatitis treatments show long-term efficacy in new clinical data

New clinical data highlights advancements in treating moderate-to-severe atopic dermatitis (eczema) using monoclonal antibodies.

Phase 2 data presented at the 2026 Pediatric Dermatology Research Alliance (PeDRA) Annual Conference shows that nemolizumab, developed by Galderma, provided early and lasting improvements in itch, sleep, and quality of life for children aged 2 to 11. The study assessed the safety and efficacy of the treatment, which blocks interleukin (IL)-31 signaling, in a pediatric population where its efficacy had not previously been established.

In a separate long-term study, Almirall presented 5-year data from the phase 3b ADlong open-label extension regarding lebrikizumab. The results, shared at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, demonstrated sustained skin clearance and itch control in adults and adolescents. At the 108-week mark, 92.9% of subjects achieved EASI-75, and 66.7% reached clear or almost-clear skin, with no new safety signals identified over the cumulative exposure period.